On October 8, Liquidia Technologies Inc rose 9.07% in regular trading, trading at $29.01 per share, with turnover of $33.38 million. The catalyst was the U.S. FDA granting Fast Track designation to Yutrepia inhaled powder for the treatment of systemic sclerosis-associated Raynaud's phenomenon, marking an important expansion beyond pulmonary arterial hypertension.

The Fast Track designation is designed to expedite development and review of therapies for serious conditions, enabling more frequent communication with the FDA and the possibility of priority review. Additionally, Yutrepia achieved net product sales of approximately $170.4 million in the second quarter, up 31% sequentially, indicating continued strong commercial momentum.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)